ALLG NHL26 A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid (Registered Trademark) consolidation added to Rituximab maintenance therapy in those remaining Positron Emission Tomography (PET) positive

"Dataset includes: - data for 37 patients with relapsed follicular lymphoma - PET response of all 37 registered patients at screening, 6 months post study treatment, and at disease progression - QoL data for all patients up to 18 months of follow-up - 2 years of Rituximab and Lenolidomide treatment data - Follow-up treatment data for all patients up to 18months - Comparison of treatment arm data for conversion of PET+ to PET - Progression Free Survival and Overall survival data "